Cargando…

Advances in Alzheimer's imaging are changing the experience of Alzheimer's disease

Neuroimaging is advancing a new definition of Alzheimer's disease (AD). Using imaging biomarkers, clinicians may begin to diagnose the disease by identifying pathology and neurodegeneration in either cognitively impaired or unimpaired adults. This “biomarker-based” diagnosis may allow clinician...

Descripción completa

Detalles Bibliográficos
Autores principales: Stites, Shana D., Milne, Richard, Karlawish, Jason
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5956938/
https://www.ncbi.nlm.nih.gov/pubmed/29780873
http://dx.doi.org/10.1016/j.dadm.2018.02.006
_version_ 1783323979031773184
author Stites, Shana D.
Milne, Richard
Karlawish, Jason
author_facet Stites, Shana D.
Milne, Richard
Karlawish, Jason
author_sort Stites, Shana D.
collection PubMed
description Neuroimaging is advancing a new definition of Alzheimer's disease (AD). Using imaging biomarkers, clinicians may begin to diagnose the disease by identifying pathology and neurodegeneration in either cognitively impaired or unimpaired adults. This “biomarker-based” diagnosis may allow clinicians novel opportunities to use interventions that either delay the onset or slow the progression of cognitive decline, but it will also bring novel challenges. How will changing the definition of AD from a clinical to a biomarker construct change the experience of living with the disease? Knowledge of AD biomarker status can affect how individuals feel about themselves (internalized stigma) and how others judge them (public stigma). Following a review of AD stigma, we appraise how advances in diagnosis may enable or interrupt its transfer from clinical to preclinical stages and then explore conceptual and pragmatic challenges to addressing stigma in routine care.
format Online
Article
Text
id pubmed-5956938
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-59569382018-05-18 Advances in Alzheimer's imaging are changing the experience of Alzheimer's disease Stites, Shana D. Milne, Richard Karlawish, Jason Alzheimers Dement (Amst) Special Section: State of the Field: Advances in Neuroimaging from the 2017 Alzheimer’s Imaging Consortium. (Guest Editors: Drs. David Wolk, Victor Villemagne & Bradford Dickerson) Neuroimaging is advancing a new definition of Alzheimer's disease (AD). Using imaging biomarkers, clinicians may begin to diagnose the disease by identifying pathology and neurodegeneration in either cognitively impaired or unimpaired adults. This “biomarker-based” diagnosis may allow clinicians novel opportunities to use interventions that either delay the onset or slow the progression of cognitive decline, but it will also bring novel challenges. How will changing the definition of AD from a clinical to a biomarker construct change the experience of living with the disease? Knowledge of AD biomarker status can affect how individuals feel about themselves (internalized stigma) and how others judge them (public stigma). Following a review of AD stigma, we appraise how advances in diagnosis may enable or interrupt its transfer from clinical to preclinical stages and then explore conceptual and pragmatic challenges to addressing stigma in routine care. Elsevier 2018-03-19 /pmc/articles/PMC5956938/ /pubmed/29780873 http://dx.doi.org/10.1016/j.dadm.2018.02.006 Text en © 2018 Published by Elsevier Inc. on behalf of the Alzheimer's Association. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Special Section: State of the Field: Advances in Neuroimaging from the 2017 Alzheimer’s Imaging Consortium. (Guest Editors: Drs. David Wolk, Victor Villemagne & Bradford Dickerson)
Stites, Shana D.
Milne, Richard
Karlawish, Jason
Advances in Alzheimer's imaging are changing the experience of Alzheimer's disease
title Advances in Alzheimer's imaging are changing the experience of Alzheimer's disease
title_full Advances in Alzheimer's imaging are changing the experience of Alzheimer's disease
title_fullStr Advances in Alzheimer's imaging are changing the experience of Alzheimer's disease
title_full_unstemmed Advances in Alzheimer's imaging are changing the experience of Alzheimer's disease
title_short Advances in Alzheimer's imaging are changing the experience of Alzheimer's disease
title_sort advances in alzheimer's imaging are changing the experience of alzheimer's disease
topic Special Section: State of the Field: Advances in Neuroimaging from the 2017 Alzheimer’s Imaging Consortium. (Guest Editors: Drs. David Wolk, Victor Villemagne & Bradford Dickerson)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5956938/
https://www.ncbi.nlm.nih.gov/pubmed/29780873
http://dx.doi.org/10.1016/j.dadm.2018.02.006
work_keys_str_mv AT stitesshanad advancesinalzheimersimagingarechangingtheexperienceofalzheimersdisease
AT milnerichard advancesinalzheimersimagingarechangingtheexperienceofalzheimersdisease
AT karlawishjason advancesinalzheimersimagingarechangingtheexperienceofalzheimersdisease